Intercell AG to Host Research & Development day in NYC.

VIENNA, Austria -- Intercell AG (VSE; ICLL) will host a Research & Development (R&D) day event in NYC: "From scientific visions to vaccine products", on Thursday October 26, beginning at 12:15 PM Eastern Time.

The program will be moderated by Intercell's CEO Gerd Zettlmeissl. An updated schedule of the day, with topics and speakers, is available at www.intercell.com.

Investors and other interested parties may attend this event and RSVP by sending an email to [e-mail] or by calling Thomas Fechtner from The Trout Group at [phone] x31. In addition, you can access this meeting by visiting the Company's Web site at www.intercell.com for a simultaneous web cast of the presentations. If you are unable to participate during the live web cast, the event will be archived on the Intercell Web site.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Wyeth, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and S. aureus, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL". For more information, please visit: www.intercell.com

This communication expressly or implicitly contains certain forward~looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially diferent from any future results, performance or achievements expressed or implied by such forward~looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward~looking statements contained herein as a result of new information, future events or otherwise.